(NASDAQ: OVID) Ovid Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.78%.
Ovid Therapeutics's earnings in 2025 is -$24,973,000.On average, 5 Wall Street analysts forecast OVID's earnings for 2025 to be -$42,665,708, with the lowest OVID earnings forecast at -$48,354,470, and the highest OVID earnings forecast at -$36,976,947. On average, 5 Wall Street analysts forecast OVID's earnings for 2026 to be -$46,221,184, with the lowest OVID earnings forecast at -$54,043,231, and the highest OVID earnings forecast at -$28,443,806.
In 2027, OVID is forecast to generate -$61,509,730 in earnings, with the lowest earnings forecast at -$64,709,658 and the highest earnings forecast at -$58,309,801.